published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsMARIPOSA, 2021 1.43 [0.42; 4.87] 1.43[0.42; 4.87]MARIPOSA, 202110%97NAnot evaluable hospital dischargedetailed resultsMARIPOSA, 2021 0.88 [0.55; 1.40] 0.88[0.55; 1.40]MARIPOSA, 202110%NAnot evaluable mechanical ventilationdetailed resultsMARIPOSA, 2021 0.88 [0.37; 2.10] 0.88[0.37; 2.10]MARIPOSA, 202110%97NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-28 21:15 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 557,635,1236,553,628,646,645,607,395 - roots T: 290